MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
Halozyme Therapeutics, Inc. (NASDAQ: HALO)*
Finance & Acquisitions: Halozyme
Parents
Halozyme Therapeutics, Inc. (NASDAQ: HALO)*
Children
2011: Halozyme Therapeutics, Inc. and Intrexon Corporation Licensing Deal Valued at $63 Million (2011)
2019: Halozyme Gets $30M from Argenx in Licensing Deal Worth Up to $530M
2022: Halozyme Therapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
2024: Halozyme Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024:Halozyme offers $2B for Evotec to expand beyond delivery tech used by J&J and Roche
2025: Halozyme Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation
Antares Pharma (NASDAQ: ATRS)
Evotec SE (NASDAQ: EVO)*
Revenue: 288 million USD (2019)
Jumps
*Key People: Halozyme
Organization & Developments: Halozyme